Clinical Trials
3 trialsNCT03878095 2026-06-01
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06441747 2026-05-06
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT03212274 2026-02-19
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting